New and emerging lipid-modifying drugs to lower LDL cholesterol
Copyright © 2021 Kosmas CE, Pantou D, Sourlas A, Papakonstantinou EJ, Echavarria Uceta R, Guzman E..
Cardiovascular disease (CVD) represents the leading cause of death worldwide. The role of low-density lipoprotein-cholesterol (LDL-C) in the pathophysiology of atherosclerosis and CVD has been well recognized. Statins are the standard of care for the management of hypercholesterolaemia, and their effectiveness in lowering LDL-C and reducing CVD risk in both primary and secondary prevention has been well established. However, several patients fail to attain optimal LDL-C goals or are intolerant to statins, especially at high doses. PCSK9 inhibitors, bempedoic acid, inclisiran, ANGPTL3 inhibitors, PPARβ/δ agonists and LXR agonists are novel or upcoming LDL-C-lowering agents that have shown promising beneficial results. This review aims to present and discuss the current clinical and scientific data pertaining to the new and emerging lipid-modifying LDL-C-lowering drugs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Drugs in context - 10(2021) vom: 26. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kosmas, Constantine E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ANGPTL3 inhibitors |
|---|
| Anmerkungen: |
Date Revised 20.11.2021 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.7573/dic.2021-8-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333331761 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333331761 | ||
| 003 | DE-627 | ||
| 005 | 20231225221440.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7573/dic.2021-8-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1111.xml |
| 035 | |a (DE-627)NLM333331761 | ||
| 035 | |a (NLM)34795777 | ||
| 035 | |a (PII)2021-8-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kosmas, Constantine E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a New and emerging lipid-modifying drugs to lower LDL cholesterol |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.11.2021 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2021 Kosmas CE, Pantou D, Sourlas A, Papakonstantinou EJ, Echavarria Uceta R, Guzman E. | ||
| 520 | |a Cardiovascular disease (CVD) represents the leading cause of death worldwide. The role of low-density lipoprotein-cholesterol (LDL-C) in the pathophysiology of atherosclerosis and CVD has been well recognized. Statins are the standard of care for the management of hypercholesterolaemia, and their effectiveness in lowering LDL-C and reducing CVD risk in both primary and secondary prevention has been well established. However, several patients fail to attain optimal LDL-C goals or are intolerant to statins, especially at high doses. PCSK9 inhibitors, bempedoic acid, inclisiran, ANGPTL3 inhibitors, PPARβ/δ agonists and LXR agonists are novel or upcoming LDL-C-lowering agents that have shown promising beneficial results. This review aims to present and discuss the current clinical and scientific data pertaining to the new and emerging lipid-modifying LDL-C-lowering drugs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a ANGPTL3 inhibitors | |
| 650 | 4 | |a LDL-C-lowering | |
| 650 | 4 | |a LXR agonists | |
| 650 | 4 | |a PCSK9 inhibitors | |
| 650 | 4 | |a PPARβ/δ agonists | |
| 650 | 4 | |a bempedoic acid | |
| 650 | 4 | |a cardiovascular disease | |
| 650 | 4 | |a inclisiran | |
| 700 | 1 | |a Pantou, Dafni |e verfasserin |4 aut | |
| 700 | 1 | |a Sourlas, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Papakonstantinou, Evangelia J |e verfasserin |4 aut | |
| 700 | 1 | |a Echavarria Uceta, Rogers |e verfasserin |4 aut | |
| 700 | 1 | |a Guzman, Eliscer |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs in context |d 2012 |g 10(2021) vom: 26. |w (DE-627)NLM234551011 |x 1745-1981 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2021 |g day:26 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7573/dic.2021-8-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2021 |b 26 | ||